Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
April 15, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and...
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
April 02, 2019 09:02 ET
|
Aptevo Therapeutics Inc.
APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and...
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
March 25, 2019 09:02 ET
|
Aptevo Therapeutics Inc.
SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
March 20, 2019 09:02 ET
|
Aptevo Therapeutics Inc.
Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 ...
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
March 18, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and...
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
March 07, 2019 09:13 ET
|
Aptevo Therapeutics Inc.
SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
March 06, 2019 16:37 ET
|
Aptevo Therapeutics Inc.
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Therapeutics Highlights Key 2019 Priorities
January 07, 2019 08:30 ET
|
Aptevo Therapeutics Inc.
ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;APVO210 Beginning Phase 1 Clinical Trial in...
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
January 03, 2019 09:02 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it...
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
December 21, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a...